Search Results 161-170 of 11960 for Hypertensive retinopathy
intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema ...
The purpose of this study is to analyze the use of ravulizumab, an inhibitor of complement activation, to target alternative complement pathway in patients with ...
For people with inherited retinal diseases, timely diagnosis, counseling and resource discussions are imperative to improve quality of life.
https://www.cdc.gov/bloodpressure/sleep.htm. Accessed April 24, 2024. Bock JM, et al. Sleep duration and hypertension: Epidemiological evidence and underlying ...
The purpose of this study is to use HOUsing-based SocioEconomic Status (HOUSES) index, an innovative housing-based, individual-level SES measure and social ...
The first U.S. consensus statement on BPA for treatment of chronic thromboembolic pulmonary hypertension (CTEPH) was published in JACC: Cardiovascular ...
Second, the investigators want to demonstrate efficacy of chronically (one week) administered SQ BNP in resistant hypertension in reducing blood pressure.
DEAR MAYO CLINIC: At my last few visits to the doctor my blood pressure was high. What causes resistant hypertension, and how is it treated if medications ...
About this study. We propose a pilot study to assess safety and benefit of renal artery ablation at the time of planned atrial fibrillation ablation.
Learn about the symptoms, diagnosis and treatment for various conditions that affect the retinas and vision. Find out when it's time to contact a doctor.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.